528 related articles for article (PubMed ID: 27896399)
1. Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells.
Wu Y; Chitranshi P; Loukotková L; Gamboa da Costa G; Beland FA; Zhang J; Fang JL
Arch Toxicol; 2017 Jun; 91(6):2405-2423. PubMed ID: 27896399
[TBL] [Abstract][Full Text] [Related]
2. Direct comparison of UDP-glucuronosyltransferase and cytochrome P450 activities in human liver microsomes, plated and suspended primary human hepatocytes from five liver donors.
den Braver-Sewradj SP; den Braver MW; Baze A; Decorde J; Fonsi M; Bachellier P; Vermeulen NPE; Commandeur JNM; Richert L; Vos JC
Eur J Pharm Sci; 2017 Nov; 109():96-110. PubMed ID: 28778465
[TBL] [Abstract][Full Text] [Related]
3. Metabolism-mediated drug interaction potential of HS-23, a new herbal drug for the treatment of sepsis in human hepatocytes and liver microsomes.
Jeong HU; Lee JY; Kwon SS; Kim JH; Kim YM; Hong SW; Yeon SH; Lee SM; Cho YY; Lee HS
Arch Pharm Res; 2015 Feb; 38(2):171-7. PubMed ID: 25052959
[TBL] [Abstract][Full Text] [Related]
4. Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytes.
Ghosal A; Hapangama N; Yuan Y; Lu X; Horne D; Patrick JE; Zbaida S
Biopharm Drug Dispos; 2003 Dec; 24(9):375-84. PubMed ID: 14689466
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures.
Yokoyama Y; Sasaki Y; Terasaki N; Kawataki T; Takekawa K; Iwase Y; Shimizu T; Sanoh S; Ohta S
Biol Pharm Bull; 2018 May; 41(5):722-732. PubMed ID: 29445054
[TBL] [Abstract][Full Text] [Related]
6. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
[TBL] [Abstract][Full Text] [Related]
7. Ethanol oxidation into acetaldehyde by 16 recombinant human cytochrome P450 isoforms: role of CYP2C isoforms in human liver microsomes.
Hamitouche S; Poupon J; Dreano Y; Amet Y; Lucas D
Toxicol Lett; 2006 Dec; 167(3):221-30. PubMed ID: 17084997
[TBL] [Abstract][Full Text] [Related]
8. Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology.
Yoshitomi S; Ikemoto K; Takahashi J; Miki H; Namba M; Asahi S
Toxicol In Vitro; 2001 Jun; 15(3):245-56. PubMed ID: 11377097
[TBL] [Abstract][Full Text] [Related]
9. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.
Parkinson A; Mudra DR; Johnson C; Dwyer A; Carroll KM
Toxicol Appl Pharmacol; 2004 Sep; 199(3):193-209. PubMed ID: 15364537
[TBL] [Abstract][Full Text] [Related]
10. Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro.
Shimokawa Y; Sasahara K; Yoda N; Mizuno K; Umehara K
Biol Pharm Bull; 2014; 37(11):1727-35. PubMed ID: 25366478
[TBL] [Abstract][Full Text] [Related]
11. Charactering the metabolism of cryptotanshinone by human P450 enzymes and uridine diphosphate glucuronosyltransferases in vitro.
Zeng J; Fan YJ; Tan B; Su HZ; Li Y; Zhang LL; Jiang J; Qiu FR
Acta Pharmacol Sin; 2018 Aug; 39(8):1393-1404. PubMed ID: 29417949
[TBL] [Abstract][Full Text] [Related]
12.
Lim SYM; Alshagga MA; Alshawsh MA; Ong CE; Pan Y
Drug Metab Pers Ther; 2021 Aug; 37(1):55-67. PubMed ID: 35146975
[TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
Utkarsh D; Loretz C; Li AP
Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
[TBL] [Abstract][Full Text] [Related]
14. Assessment of induction of cytochrome P450 by NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, in primary cultures of human hepatocytes and in female rat liver.
Morioka Y; Nishimura M; Imai T; Suzuki S; Harada M; Satoh T; Naito S
Drug Metab Pharmacokinet; 2006 Feb; 21(1):19-28. PubMed ID: 16547390
[TBL] [Abstract][Full Text] [Related]
15. Distinction between human cytochrome P450 (CYP) isoforms and identification of new phosphorylation sites by mass spectrometry.
Redlich G; Zanger UM; Riedmaier S; Bache N; Giessing AB; Eisenacher M; Stephan C; Meyer HE; Jensen ON; Marcus K
J Proteome Res; 2008 Nov; 7(11):4678-88. PubMed ID: 18828626
[TBL] [Abstract][Full Text] [Related]
16. In vitro metabolism of nobiletin, a polymethoxy-flavonoid, by human liver microsomes and cytochrome P450.
Koga N; Ohta C; Kato Y; Haraguchi K; Endo T; Ogawa K; Ohta H; Yano M
Xenobiotica; 2011 Nov; 41(11):927-33. PubMed ID: 21726170
[TBL] [Abstract][Full Text] [Related]
17. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine.
Fang J; Coutts RT; McKenna KF; Baker GB
Naunyn Schmiedebergs Arch Pharmacol; 1998 Nov; 358(5):592-9. PubMed ID: 9840430
[TBL] [Abstract][Full Text] [Related]
18. Effect of honokiol on the induction of drug-metabolizing enzymes in human hepatocytes.
Cho YY; Jeong HU; Kim JH; Lee HS
Drug Des Devel Ther; 2014; 8():2137-45. PubMed ID: 25395831
[TBL] [Abstract][Full Text] [Related]
19. Absolute protein quantification of clinically relevant cytochrome P450 enzymes and UDP-glucuronosyltransferases by mass spectrometry-based targeted proteomics.
Gröer C; Busch D; Patrzyk M; Beyer K; Busemann A; Heidecke CD; Drozdzik M; Siegmund W; Oswald S
J Pharm Biomed Anal; 2014 Nov; 100():393-401. PubMed ID: 25218440
[TBL] [Abstract][Full Text] [Related]
20. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.
Muschler E; Lal J; Jetter A; Rattay A; Zanger U; Zadoyan G; Fuhr U; Kirchheiner J
Basic Clin Pharmacol Toxicol; 2009 Dec; 105(6):374-9. PubMed ID: 19614891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
